XOMA Royalty Corporation (NASDAQ:XOMA) Receives Consensus Recommendation of “Hold” from Analysts

XOMA Royalty Corporation (NASDAQ:XOMA) has earned a consensus recommendation of “Hold” from the seven brokerages that are currently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $53.75.

A number of analysts recently issued reports on XOMA shares. Weiss Ratings raised XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 29th. Zacks Research raised XOMA Royalty from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 8th. Lucid Cap Mkts cut XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 27th. Benchmark cut XOMA Royalty from a “buy” rating to a “hold” rating in a research note on Friday, May 22nd. Finally, TD Cowen raised XOMA Royalty to a “hold” rating in a research note on Friday, February 13th.

Hedge Funds Weigh In On XOMA Royalty

A number of large investors have recently bought and sold shares of XOMA. JPMorgan Chase & Co. boosted its holdings in shares of XOMA Royalty by 13.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 543 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of XOMA Royalty by 3,436.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 756 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in shares of XOMA Royalty in the 4th quarter valued at approximately $27,000. Dimensional Fund Advisors LP raised its stake in XOMA Royalty by 4.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 29,190 shares of the biotechnology company’s stock valued at $1,124,000 after acquiring an additional 1,269 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in XOMA Royalty by 203.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 1,523 shares during the period. Institutional investors and hedge funds own 95.92% of the company’s stock.

XOMA Royalty Stock Performance

Shares of XOMA stock opened at $41.92 on Thursday. The stock has a 50-day moving average of $39.36 and a 200-day moving average of $31.54. XOMA Royalty has a one year low of $22.29 and a one year high of $42.81. The company has a debt-to-equity ratio of 0.96, a current ratio of 3.59 and a quick ratio of 3.59. The stock has a market cap of $525.72 million, a PE ratio of 26.70 and a beta of 0.88.

XOMA Royalty (NASDAQ:XOMA) last posted its earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). XOMA Royalty had a return on equity of 12.56% and a net margin of 53.46%.The business had revenue of $12.32 million for the quarter, compared to the consensus estimate of $13.91 million. As a group, sell-side analysts expect that XOMA Royalty will post 0.9 earnings per share for the current year.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.